Sanofi-Aventis offer
This article was originally published in The Tan Sheet
Executive Summary
Sanofi-Synthelabo extends its offer for Aventis U.S. shareholders to exchange their shares for Sanofi stock until June 30, Sanofi announces. The original deadline of May 28 was extended pending a decision by the French stock market regulator Autrite des Marches Financiers to set an expiration date. Sanofi has articulated a desire to close the $65 bil. merger in the second quarter. The firm also is awaiting final clearance from the Federal Trade Commission. Aventis accepted Sanofi's offer April 25 (1"The Tan Sheet" May 3, 2004, p. 8)...
You may also be interested in...
Sunscreen Group Suggests User Fees To Expedite Ingredient Reviews
The Public Access to SunScreens Coalition will recommend a user fee program to improve FDA’s work on TEAs for OTC ingredients. “Despite a number of OTC applications waiting for approval for several years, FDA has not completed the review of applications for any new sunscreen components,” PASS says.
Sunscreen Group Suggests User Fees To Expedite Ingredient Reviews
The Public Access to SunScreens Coalition will recommend a user fee program to improve FDA’s work on TEAs for OTC ingredients. “Despite a number of OTC applications waiting for approval for several years, FDA has not completed the review of applications for any new sunscreen components,” PASS says.
Sequestration Could Drive An FDA Resources Review
FDA and advocates wait to see how an estimated 7.8% budget cut would be implemented, if enacted. Former agency officials say sequestration could lead to hiring freezes and program delays.